385 related articles for article (PubMed ID: 36107379)
1. COVID-19-associated pulmonary aspergillosis (CAPA) in Iranian patients admitted with severe COVID-19 pneumonia.
Erami M; Hashemi SJ; Raiesi O; Fattahi M; Getso MI; Momen-Heravi M; Daie Ghazvini R; Khodavaisy S; Parviz S; Mehri N; Babaei M
Infection; 2023 Feb; 51(1):223-230. PubMed ID: 36107379
[TBL] [Abstract][Full Text] [Related]
2. Genomic and Phenotypic Analysis of COVID-19-Associated Pulmonary Aspergillosis Isolates of Aspergillus fumigatus.
Steenwyk JL; Mead ME; de Castro PA; Valero C; Damasio A; Dos Santos RAC; Labella AL; Li Y; Knowles SL; Raja HA; Oberlies NH; Zhou X; Cornely OA; Fuchs F; Koehler P; Goldman GH; Rokas A
Microbiol Spectr; 2021 Sep; 9(1):e0001021. PubMed ID: 34106569
[TBL] [Abstract][Full Text] [Related]
3. [Expert consensus on diagnosis and treatment of severe COVID-19 associated pulmonary
;
Zhonghua Jie He He Hu Xi Za Zhi; 2024 Jan; 47(1):10-23. PubMed ID: 38062689
[TBL] [Abstract][Full Text] [Related]
4. COVID-19-associated pulmonary aspergillosis (CAPA) in hematological patients: Could antifungal prophylaxis be necessary? A nationwide study.
Tamayo-Velasco Á; López-Herrero R; Gómez-García LM; Sánchez-de Prada L; Aguilar-Monserrate G; Martín-Fernández M; Bardají-Carrillo M; Álvaro-Meca A; Tamayo E; Resino S; Miramontes-González JP; Peñarrubia-Ponce MJ
J Infect Public Health; 2024 Jun; 17(6):939-946. PubMed ID: 38613930
[TBL] [Abstract][Full Text] [Related]
5. COVID-19-associated pulmonary aspergillosis (CAPA): identification of Aspergillus species and determination of antifungal susceptibility profiles.
Ozturk A; Bozok T; Erdogan M; Ibrahim BM; Bozok TS
Folia Microbiol (Praha); 2023 Dec; 68(6):951-959. PubMed ID: 37294497
[TBL] [Abstract][Full Text] [Related]
6. Significance of Aspergillus spp. isolation in defining cases of COVID-19 Associated Pulmonary Aspergillosis - CAPA.
Cocio TA; Siqueira LPM; Riciluca KCT; Gimenes VMF; de Andrade TS; Benard G; Martínez R; Bollela VR
Braz J Infect Dis; 2023; 27(4):102793. PubMed ID: 37507102
[TBL] [Abstract][Full Text] [Related]
7. Clinical characteristics, bacterial coinfections and outcomes in COVID-19-associated pulmonary aspergillosis in a third-level Mexican hospital during the COVID-19 pre-vaccination era.
Hernández-Silva G; Corzo-León DE; Becerril-Vargas E; Peralta-Prado AB; Odalis RG; Morales-Villarreal F; Ríos-Ayala MA; Alonso TG; Agustín FD; Ramón AF; Hugo AV
Mycoses; 2024 Jan; 67(1):e13693. PubMed ID: 38214372
[TBL] [Abstract][Full Text] [Related]
8. COVID-19-associated pulmonary aspergillosis in ICU patients in a German reference centre: Phenotypic and molecular characterisation of Aspergillus fumigatus isolates.
Kirchhoff L; Braun LM; Schmidt D; Dittmer S; Dedy J; Herbstreit F; Stauf R; Steckel NK; Buer J; Rath PM; Steinmann J; Verhasselt HL
Mycoses; 2022 Apr; 65(4):458-465. PubMed ID: 35138651
[TBL] [Abstract][Full Text] [Related]
9. A Tale of Two Hospitals: Comparing CAPA Infections in Two ICUs During the Spanish Fourth Pandemic Wave.
Sánchez-Castellano MÁ; Marcelo C; Marco J; Figueira-Iglesias JC; García-Rodríguez J
Mycopathologia; 2023 Aug; 188(4):335-344. PubMed ID: 37256502
[TBL] [Abstract][Full Text] [Related]
10. Antifungal activities of posaconazole, ravuconazole, and voriconazole compared to those of itraconazole and amphotericin B against 239 clinical isolates of Aspergillus spp. and other filamentous fungi: report from SENTRY Antimicrobial Surveillance Program, 2000.
Pfaller MA; Messer SA; Hollis RJ; Jones RN;
Antimicrob Agents Chemother; 2002 Apr; 46(4):1032-7. PubMed ID: 11897586
[TBL] [Abstract][Full Text] [Related]
11. A prospective survey of Aspergillus spp. in respiratory tract samples: prevalence, clinical impact and antifungal susceptibility.
Mortensen KL; Johansen HK; Fuursted K; Knudsen JD; Gahrn-Hansen B; Jensen RH; Howard SJ; Arendrup MC
Eur J Clin Microbiol Infect Dis; 2011 Nov; 30(11):1355-63. PubMed ID: 21541671
[TBL] [Abstract][Full Text] [Related]
12. Comparison of the Sensititre YeastOne and CLSI M38-A2 Microdilution Methods in Determining the Activity of Amphotericin B, Itraconazole, Voriconazole, and Posaconazole against Aspergillus Species.
Wang HC; Hsieh MI; Choi PC; Wu CJ
J Clin Microbiol; 2018 Oct; 56(10):. PubMed ID: 30093391
[TBL] [Abstract][Full Text] [Related]
13. Molecular identification, phylogenetic analysis and antifungal susceptibility patterns of Aspergillusnidulans complex and Aspergillusterreus complex isolated from clinical specimens.
Mohamadnia A; Salehi Z; Namvar Z; Tabarsi P; Pourabdollah-Toutkaboni M; Rezaie S; Marjani M; Moniri A; Abtahian Z; Mahdaviani SA; Mortezaee V; Askari E; Sharifynia S
J Mycol Med; 2020 Sep; 30(3):101004. PubMed ID: 32534826
[TBL] [Abstract][Full Text] [Related]
14. Multicenter Study of Susceptibility of Aspergillus Species Isolated from Iranian University Hospitals to Seven Antifungal Agents.
Badiee P; Boekhout T; Zarei Mahmoudabadi A; Mohammadi R; Ayatollahi Mousavi SA; Najafzadeh MJ; Soltani J; Hashemi J; Diba K; Ghadimi-Moghadam A; Salimi-Khorashad AR; Shokohi T; Amin Shahidi M; Ghasemi F; Jafarian H
Microbiol Spectr; 2022 Jun; 10(3):e0253921. PubMed ID: 35579442
[TBL] [Abstract][Full Text] [Related]
15. Defining and managing COVID-19-associated pulmonary aspergillosis: the 2020 ECMM/ISHAM consensus criteria for research and clinical guidance.
Koehler P; Bassetti M; Chakrabarti A; Chen SCA; Colombo AL; Hoenigl M; Klimko N; Lass-Flörl C; Oladele RO; Vinh DC; Zhu LP; Böll B; Brüggemann R; Gangneux JP; Perfect JR; Patterson TF; Persigehl T; Meis JF; Ostrosky-Zeichner L; White PL; Verweij PE; Cornely OA; ; ; ; ; ; ; ; ; ; ; ; ; ;
Lancet Infect Dis; 2021 Jun; 21(6):e149-e162. PubMed ID: 33333012
[TBL] [Abstract][Full Text] [Related]
16. COVID-19-Associated Pulmonary Aspergillosis (CAPA).
Dimopoulos G; Almyroudi MP; Myrianthefs P; Rello J
J Intensive Med; 2021 Oct; 1(2):71-80. PubMed ID: 36785564
[TBL] [Abstract][Full Text] [Related]
17. Successful treatment of proven coronavirus disease 2019-associated pulmonary aspergillosis with liposomal amphotericin B in a patient with bronchiolitis obliterans syndrome after allogeneic hematopoietic stem cell transplantation.
Nakaya Y; Nakashima Y; Harada N; Yamada K; Makuuchi Y; Kuno M; Takakuwa T; Okamura H; Nanno S; Nishimoto M; Koh H; Nakagama Y; Kido Y; Kanno T; Suzuki T; Nakamae H; Kakeya H; Hino M
J Infect Chemother; 2023 Feb; 29(2):223-227. PubMed ID: 36379403
[TBL] [Abstract][Full Text] [Related]
18. Lung epithelial and myeloid innate immunity in influenza-associated or COVID-19-associated pulmonary aspergillosis: an observational study.
Feys S; Gonçalves SM; Khan M; Choi S; Boeckx B; Chatelain D; Cunha C; Debaveye Y; Hermans G; Hertoghs M; Humblet-Baron S; Jacobs C; Lagrou K; Marcelis L; Maizel J; Meersseman P; Nyga R; Seldeslachts L; Starick MR; Thevissen K; Vandenbriele C; Vanderbeke L; Vande Velde G; Van Regenmortel N; Vanstapel A; Vanmassenhove S; Wilmer A; Van De Veerdonk FL; De Hertogh G; Mombaerts P; Lambrechts D; Carvalho A; Van Weyenbergh J; Wauters J
Lancet Respir Med; 2022 Dec; 10(12):1147-1159. PubMed ID: 36029799
[TBL] [Abstract][Full Text] [Related]
19. Susceptibility testing of sequential isolates of Aspergillus fumigatus recovered from treated patients.
Dannaoui E; Meletiadis J; Tortorano AM; Symoens F; Nolard N; Viviani MA; Piens MA; Lebeau B; Verweij PE; Grillot R; And The Ebga Network
J Med Microbiol; 2004 Feb; 53(Pt 2):129-134. PubMed ID: 14729934
[TBL] [Abstract][Full Text] [Related]
20. Time-Kill Kinetics and In Vitro Antifungal Susceptibility of Non-fumigatus Aspergillus Species Isolated from Patients with Ocular Mycoses.
Öz Y; Özdemir HG; Gökbolat E; Kiraz N; Ilkit M; Seyedmousavi S
Mycopathologia; 2016 Apr; 181(3-4):225-33. PubMed ID: 26612621
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
